24 results about "Drug detection" patented technology

This application discloses a portable drug detection device and method, relating to the field of drug identification technology, with the main objective of addressing the problem of poor detection effectiveness in existing drug testing methods. It includes: a Raman spectroscopy component, an ion mobility spectrometry component, a processor, a power module, a display component, and a sample inlet module disposed on the ion mobility spectrometry component. The processor is electrically connected to the Raman spectroscopy component, the ion mobility spectrometry component, and the display component, and is used to identify and process the spectra acquired by the Raman spectroscopy component and the ion mobility spectrometry component to obtain drug detection results. The power module is electrically connected to the Raman spectroscopy component, the ion mobility spectrometry component, and the processor, and is used to provide power. The display component is used to display the drug detection results. The sample inlet module is used to insert sample test strips.

This invention provides a method for constructing and applying a fingerprint spectrum of Chushi Weiling Decoction, belonging to the field of drug detection technology. The method involves first preparing a test solution using Chushi Weiling Decoction, then using acetonitrile (A)-0.18~0.22wt% formic acid aqueous solution as the mobile phase, and obtaining the fingerprint spectrum of Chushi Weiling Decoction through high-performance liquid chromatography (HPLC). A standard fingerprint spectrum is then established using the "Similarity Evaluation System for Chromatographic Fingerprint Spectrum of Traditional Chinese Medicine" for quality evaluation or control throughout the research, development, production, and clinical application of Chushi Weiling Decoction. This invention's method for constructing the fingerprint spectrum of Chushi Weiling Decoction enables the detection of the main medicinal components in Chushi Weiling Decoction solely through HPLC, thus providing a more comprehensive reflection of the quality status of Chushi Weiling Decoction.

The application discloses a kind of chiral drug detection methods based on polarization raman microspectral system, based on an optical detection system including signal excitation module, polarizing module, detection polarization module and raman spectrum detection module;Through signal excitation module collimation is carried out to excitation light, obtains the corresponding polarization state of excitation light after polarizing module, then the polarized light is transmitted to sample, finally the raman signal of sample is transmitted to raman spectrum detection module by detection polarization module.The application has the advantages compared with prior art: using self-built polarization raman spectrum detection system, the configuration identification of enantiomer and accurate quantitative analysis of effective drug component are carried out to chiral drug, and a more comprehensive method is provided for the research of chiral drug.

This invention relates to the field of drug detection technology, specifically to a method for detecting nitrogen oxide impurities in vonoprazan fumarate tablets and its application. The invention employs liquid chromatography-mass spectrometry (LC-MS) to detect the nitrogen oxide impurities in the sample. The detection method provided by this invention can achieve qualitative and quantitative analysis of nitrogen oxide impurities in vonoprazan fumarate tablets, and has advantages such as high impurity separation, good specificity, high precision, good repeatability, and high sensitivity. The method is accurate and reliable and can be widely applied to the quality testing of vonoprazan fumarate tablets.

The application provides a construction method and a content determination method of a synovitis preparation characteristic spectrum, and belongs to the technical field of drug detection. The construction method is that a test sample solution is prepared by using the synovitis preparation, then acetonitrile-0.08-0.12wt% formic acid aqueous solution is used as a mobile phase, high performance liquid chromatography detection is carried out, the characteristic spectrum of the synovitis preparation is obtained, and the content of components in the synovitis preparation is further determined. The method can comprehensively cover the key active components of core medicinal materials in the prescription of the synovitis preparation, realizes the synchronous detection of multiple categories and multiple target components, and completely solves the defects of single quality control index and incomplete coverage in the prior art.

The application relates to the field of tail gas active carbon adsorption technology, in particular to a drug detection and treatment device, which comprises an adsorption mounting piece, the two sides of the adsorption mounting piece are respectively provided with closed control pieces, the two closed control pieces are used for closing the adsorption mounting piece; an active carbon adsorption accessory is arranged in the adsorption mounting piece; the active carbon adsorption accessory is used for adsorbing toxic substances in tail gas; a hierarchical isolation piece is fixedly arranged on the active carbon adsorption accessory; the hierarchical isolation piece is arranged in the adsorption mounting piece; a pressure compensation piece is adopted; with the saturation and blockage aggravation of active carbon particles, the structure can automatically increase the effective air inlet area, increase the effective air inlet area, and always maintain the airflow stability and the ventilation resistance in a reasonable range; the problem that the current drug detection active carbon treatment device cannot automatically adapt to the compensation of the air inlet area with the increase of the active carbon blockage degree is solved.

The present application relates to the technical field of drug detection, in particular to a method for determining the content of six components in Shengmai Yin soft capsules based on one measurement multiple evaluation. The method uses schisandrol A as an internal standard for one measurement multiple evaluation, establishes the relative correction factors of schisandrol B, angeloylgomisin H, schisantherin A, schisantherin B and schisantherin C, and calculates the content of the above components in Shengmai Yin soft capsules (Dangshen Fang) through the relative correction factors. The specific steps include: preparation of test sample solution; preparation of reference sample solution; chromatographic conditions and system suitability test; determination and calculation. The present application overcomes the single and one-sidedness of the quality control of Shengmai Yin soft capsules (Dangshen Fang), and has important significance for further improving the drug quality control standard and ensuring the clinical efficacy of drugs.

The present application belongs to the technical field of drug detection method, and particularly relates to a method for detecting drugs in atmospheric environment samples, comprising the following steps: using the adsorption material of a gas sampling instrument to adsorb the drugs in the gas; after the material adsorbs the drugs, using ultrasonic extraction in an organic solvent or a high-temperature heating method to resolve the drugs; and using high-sensitivity mass spectrometry, molecular immunocolloidal gold or fluorescence method to detect the resolved drugs. The detection method can qualitatively and quantitatively detect the drugs in the atmosphere, and is also suitable for detecting the drugs in the exhaled gas of drug users, and contains new psychoactive drugs such as amphetamines, opioids and synthetic cannabis.

This application relates to the technical field of clinical therapeutic drug monitoring, specifically disclosing a detection kit and method for triazole antifungal drugs. The triazole antifungal drug detection kit disclosed in this application includes an in-situ ionization kit and an isotope internal standard working solution; the isotope internal standard working solution is diluted with acetonitrile, isopropanol, and ammonium acetate in a volume ratio of 20:(5-10):(1-5). This application also discloses a method for detecting triazole antifungal drugs using the above detection kit. The detection kit and method provided in this application for quantitative detection of triazole antifungal drugs have the advantages of simple operation, on-demand testing, and speed, and the detection accuracy is high. It can provide immediate feedback on the blood drug concentration in the patient, thereby adjusting the dosage and maximizing patient benefit.

The present application relates to a kind of high-pressure discharge leak detection methods of double-chamber bag packaging system, belong to the technical field of drug detection.The method includes the following steps: preparation contains 3~10 μm pore size double-chamber positive sample and negative sample, carry out high-pressure discharge detection under (7~8) ±0.1KV output voltage, 250~300Hz frequency, respectively record minimum positive detection value M min And maximum negative detection value M max , according to formula (M min +m max ) / 2 Calculate leakage threshold (and 1.5m max ≤M min ).The present application breaks through the limitation of traditional step-by-step detection, realizes double-chamber synchronous leak detection, avoids the parameter switching and electrode error caused by chamber detection, is suitable for different pH complex preparation (such as sodium bicarbonate hemofiltration replacement fluid etc.), can detect ≥3 μm micro leakage, detection efficiency is doubled, result is accurate and reliable, and cost is significantly reduced, effectively guarantees the quality of product and clinical drug safety.

This invention belongs to the field of drug detection technology, and relates to a platinum-iridium bimetallic nanozyme, its preparation method, and its application in immunochromatographic detection. The method includes: first, preparing a bimetallic nanozyme with a platinum core and an iridium shell; then, conjugating it with an antibody to create a colorimetric enhanced immunolabel. Based on this, a competitive immunochromatographic test strip is constructed, with the corresponding drug antigen immobilized on the T line and a quality control capture agent immobilized on the C line. During detection, the sample and label are mixed and added dropwise. If the sample does not contain the target drug, the labeled antibody binds to the antigen on the T line, resulting in color development; if the target drug is present, it competes with the T line for binding to the labeled antibody, leading to a weakening of the T line signal. A colorimetric solution is added, utilizing the catalytic activity of the nanozyme to amplify the signal, significantly improving sensitivity. This invention achieves detection limits of 0.41 ng / mL for vancomycin and 0.12 ng / mL for chlorpheniramine maleate, exhibiting advantages such as speed, high sensitivity, and ease of operation, making it suitable for therapeutic drug monitoring and trace drug residue detection.

The application discloses a kind of shentong zhuyu decoction fingerprint construction method and application, belong to the technical field of drug detection.The application is detected by high performance liquid chromatography to several batches of shentong zhuyu decoction by the selection of mobile phase and the cooperation of chromatographic column, the high performance liquid chromatography of different batches of shentong zhuyu decoction is compared, obtains the common peak containing loganic acid, amygdalin, hydroxyl safflower yellow pigment A, aniseed acid, qianghuo alcohol, isoeucommarin, ammonium glycyrrhizinate, kaempferol characteristic peak, and the fingerprint of shentong zhuyu decoction is constructed according to the common peak.The fingerprint constructed by the application can better detect 12 medicinal materials, shorten the detection time of single sample to 125 min or less, improve efficiency, and improve the quality control level of product.

The utility model provides a kind of drug detection dissolution instrument constant-temperature liquid supply system, including constant-temperature storage tank, ultrasonic defoaming device, peristaltic pump and three-way electromagnetic valve, wherein: constant-temperature storage tank is connected two interfaces of three-way electromagnetic valve by inlet pipe and reflux pipe respectively, the third interface of three-way electromagnetic valve is connected with dissolution instrument, and ultrasonic defoaming device and peristaltic pump are installed on inlet pipe.The utility model is improved and innovated to existing drug detection dissolution instrument, additional constant-temperature storage tank, ultrasonic defoaming device, peristaltic pump and several three-way electromagnetic valve, can be automatically quantitatively added dissolution medium according to need, while ultrasonic removes bubble in dissolution medium and automatically heats dissolution medium, greatly shorten test time, improve test efficiency and ensure the accuracy of test result.

Provided is a mammalian derived cell model which can be used in anti-aging drugs. The mammalian-derived extracembryonic trophoblast cell model is an early mammalian-derived extracembryonic stage. The change model of differentiation of cells into exoembryonic trophoblastic cells / organoids and the aging evaluation index system can be used various anti-aging research and target testing, anti-aging drug detection, screening, identification and innovative drugs / natural products Research and development of chemicals, and / or health foods and additives. It is helpful to screen and identify many resistances Candidate targets for aging can be further mechanized and functionally validated for future therapeutic use. The Screening of anti-aging drugs or natural products will produce huge economic and social benefits.

The present application belongs to the technical field of drug detection, and provides a broad-spectrum aptamer for recognizing 22 synthetic cannabinoids and an application thereof to solve the problem of detecting synthetic cannabinoids. The broad-spectrum aptamer is a single-stranded DNA molecule sequence as shown in SEQ ID NO: 5. The present application takes two existing nucleic acid aptamers as original aptamers, preliminarily predicts the binding mechanism of the nucleic acid aptamers and synthetic cannabinoids through molecular docking, further analyzes the interaction between the nucleic acid aptamers and the target in the base level through molecular dynamics simulation, optimizes the nucleic acid aptamers by truncation, and screens out aptamers capable of highly specifically recognizing 22 synthetic cannabinoids, which are few in base number, good in stability, easy to synthesize, and easy to modify or label functional groups. The aptamers can distinguish synthetic cannabinoids from other common drugs, verify the reliability thereof, can stably bind to 22 synthetic cannabinoids, and exhibit broad-spectrum recognition ability for synthetic cannabinoids.

This invention discloses a drug content detection device, relating to the field of drug detection technology. It includes a device housing and an operation panel. The top of the housing has a printing component, and the bottom has a detection port. The operation panel is mounted on the housing, and a heat dissipation groove is located on the rear side of the housing. It also includes a mounting shell fixed to the outside of the housing. Rectangular slots communicating with the mounting shell are provided at four positions (front, back, left, and right). Two transmission rods are symmetrically arranged inside the mounting shell, and both ends of the two transmission rods are connected to anti-drop units. This invention utilizes multiple retractable anti-drop plates (first and second types) to extend simultaneously during use, providing comprehensive protection for the top, bottom, and sides of the housing. This effectively buffers the impact of accidental drops or collisions, reducing the risk of damage to the precision detection components inside the device.

The application relates to image processing and provides a drug image recognition method, an electronic device and a storage medium. The method comprises the following steps: acquiring multiple drug images and a to-be-tested drug image, acquiring a pre-trained drug detection model, the drug detection model comprising a position detection network, a character recognition network and a category recognition network, inputting the multiple drug images into the position detection network to obtain multiple target images, generating multiple character feature matrices according to the multiple target images and the character recognition network, inputting the multiple target images into the category recognition network to obtain multiple image feature matrices, generating a reference matrix according to each character feature matrix and the corresponding image feature matrix, processing the to-be-tested drug image based on the drug detection model to obtain a to-be-tested matrix, and generating a recognition result of the to-be-tested drug image according to the similarity between the to-be-tested matrix and each reference matrix, so that the accuracy of drug image recognition is improved.

This application relates to the field of drug detection technology, and provides a method for detecting the purity of enterokinase protein. The method uses octadecylsilane-bonded silica gel as the packing material, trifluoroacetic acid aqueous solution as mobile phase A, and trifluoroacetic acid acetonitrile solution as mobile phase B, employing a specific elution procedure. This method shortens the detection time while improving the separation effect of enterokinase protein components, resulting in good separation. The method is simple, and exhibits high precision, stability, and repeatability. Therefore, it can comprehensively and rapidly detect the purity of enterokinase protein, which is beneficial for the quality control of enterokinase and thus helps improve the safety and stability of the drug.

Provided is a method for detecting a drug antibody in a specimen. In the present disclosure, the drug antibody is detected by flow cytometry for the first time. During the detection, self cells of a patient are used as indicator cells. Moreover, nine systems are set up, including: a blank system, a negative control system, a positive control system, a self—control system, a drug—sensitized self—cell control system, a drug—antibody reaction detection system, an enzyme—sensitized self—control system, an enzyme—reaction drug detection system, and an enzyme—reaction drug control system. The method avoids interference from autoantibodies and irregular antibodies of red blood cells, and also avoids a false positive result of detection caused by combination of enzymes or drugs with self red blood cells. The method for detecting a drug antibody can simultaneously detect an affinity of the drug antibody to red blood cells and identify a type of the drug antibody.

This invention belongs to the field of drug detection technology, and discloses a flexible SERS substrate, its preparation method, and its application. The preparation method includes: Step S1, preparing PVP-coated AgNPs based on Citrate-Ag colloid; Step S2, using PDMS as a flexible substrate, transferring the AgNPs sol to the PDMS surface to form a PDMS@Citrate-Ag flexible SERS substrate. The flexible SERS substrate is the substrate obtained by the above method. It also includes a method for detecting narcotic and psychotropic drugs based on the flexible SERS substrate, comprising the following steps: Step S1, contacting the narcotic and psychotropic drug to be tested with the flexible SERS substrate and performing SERS measurement using a Raman spectrometer; Step S2, introducing a dSERS strategy to perform digital quantitative analysis of the target narcotic and psychotropic drug. The flexible substrate of this invention can meet the needs of rapid on-site detection of narcotic and psychotropic drugs in various scenarios, and the dSERS strategy can solve the problem of false negatives caused by low content, cumulative abuse, and interference from complex matrices. The combination of the two is beneficial to promoting the scientific rigor and reliability of drug detection in drug control work.

This invention belongs to the field of drug detection technology, specifically relating to a method for detecting O-nordrod and its related substances using HPLC. The test solution, blank solution, reference solution, and impurity reference solution are injected into the HPLC instrument, and the chromatograms are recorded. The content of O-nordrod and its related substances in the test solution is calculated using the peak area normalization method. The related substances include one or more of impurities A, B, C, D, or E. This invention exhibits good specificity, robustness, and stability, as well as excellent precision and accuracy.

This invention discloses a synthetic cannabinoid monoclonal antibody and its application in the preparation of a detection kit for synthetic cannabinoids and structural analogues, belonging to the field of drug detection technology. The amino acid sequence of the heavy chain variable region of the synthetic cannabinoid monoclonal antibody is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2. The monoclonal antibody of this invention can effectively recognize 29 synthetic cannabinoids and structural analogues. This invention utilizes this monoclonal antibody to prepare a kit for detecting synthetic cannabinoids, which can efficiently detect synthetic cannabinoids or their metabolites in human urine. It is used for on-site screening of drug use and has significant advantages such as rapid detection, high sensitivity, broad spectrum, and suitability for rapid on-site screening.